Cholecystokinin tetrapeptide improves water maze performance of neonatally 6-hydroxydopamine-lesioned young rats

Pharmacology Biochemistry and Behavior

Volumn 79, Issue 1, 2004, Pages 109-117

  Rex, André ^a   Fink, Heidrun ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Boc CCK 4; Dopamine depletion; Learning; Lesion; Memory; Rat; Water maze

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DOPAMINE; OXIDOPAMINE; TETRAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN INJURY; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; FEMALE; LEARNING; MALE; MAZE TEST; MEMORY; NEUROTRANSMISSION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING; TASK PERFORMANCE;

ANIMALS; ANIMALS, NEWBORN; BODY WEIGHT; BRAIN CHEMISTRY; DOPAMINE; FEMALE; HYPERKINESIS; MAZE LEARNING; MEMORY; MOTOR ACTIVITY; OXIDOPAMINE; PREGNANCY; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; SWIMMING; SYMPATHECTOMY, CHEMICAL; TETRAGASTRIN;

EID: 4544297918     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.06.008     Document Type: Article

References (61)

1. P.M. Adams, J.D. Fabricant, and M.S. Legator Cyclophosphamide-induced spermatogenic effects detected in the F1 generation by behavioral testing Science 211 1981 80 82
2. J.S. Andrews Possible confounding influence of strain, age and gender on cognitive performance in rats Cogn. Brain Res. 3 1996 251 267
3. T. Archer, W. Danysz, A. Frederiksson, G. Jonsson, I. Luthman, and E. Sundström Neonatal 6-hydroxydopamine-induced dopamine-depletions: motoractivity and performance in maze learning Pharmacol. Biochem. Behav. 31 1988 357 364
4. T. Archer, T. Palomo, R. McArthur, and A. Fredriksson Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment Neurotox. Res. 5 2003 95 110
5. M.C. Beinfeld An introduction to neuronal cholecystokinin Peptides 22 2001 1197 1200
6. M.C. Beinfeld What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization Life Sci. 73 2003 643 654
7. B. Costall, R.J. Naylor, and V. Nohria Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity Eur. J. Pharmacol. 50 1978 39 50
8. J.N. Crawley Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway J. Neurosci. 12 1992 3380 3391
9. J.N. Crawley, and R.L. Corwin Biological actions of cholecystokinin Peptides 15 1994 731 755
10. V. Dauge, and I. Lena CCK in anxiety and cognitive processes Neurosci. Biobehav. Rev. 22 1998 815 825
11. V. Dauge, F. Beslot, T. Matsui, and B.P. Roques Mutant mice lacking the cholecystokinin2 receptor show a dopamine-dependent hyperactivity and a behavioral sensitization to morphine Neurosci. Lett. 306 2001 41 44
12. R. D'Hooge, and P.P. De Deyn Applications of the Morris water maze in the study of learning and memory Brain Res. Rev. 36 2001 60 90
13. W.H. Drinkenburg, P. Vijn, M.G. Martorana, M. Dickson, and W. van Schaijk A novel automated apomorphine climbing test Proceeding of Measuring Behavior 2000, 3rd International Congress on Methods and Techniques in Behavioral Research, Nijmegen 2000
14. H.R. Feeser, and L.A. Raskin Effects of neonatal dopamine depletion on spatial ability during ontogeny Behav. Neurosci. 101 1987 812 818
15. H. Fink, R. Morgenstern, and T. Ott CCK-8 modulates D2 receptor agonist-induced hypermotility in the nucleus accumbens Brain Res. Bull. 26 1991 437 440
16. H. Fink, A. Rex, M. Voits, and J.P. Voigt Major biological actions of CCKâ€"a critical evaluation of research findings Exp. Brain Res. 123 1998 77 83
17. J.L. Fobes, and M.E. Olds Effects of neonatal 6-hydroxydopamine treatment on catecholamine levels and behavior during development and adulthood Psychopharmacology 73 1981 27 30
18. K.M. Frick, E.T. Stillner, and J. Berger-Sweeney Mice are not little rats: species differences in a one-day water maze task NeuroReport 11 2000 3461 3465
19. I. Fried, C.L. Wilson, J.W. Morrow, K.A. Cameron, E.D. Behnke, and L.C. Ackerson Increased dopamine release in the human amygdala during performance of cognitive tasks Nat. Neurosci. 4 2001 201 206
20. A. Gasbarri, A. Sulli, R. Innocenzi, C. Pacitti, and J.D. Brioni Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat Neuroscience 74 1996 1037 1044
21. P. Gerhardt, M. Voits, H. Fink, and J.P. Huston Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S Peptides 15 1994 689 697
22. G.A. Heise Behavioral methods for measuring effects of drugs on learning and memory in animals Med. Res. Rev. 4 1984 535 558
23. D.R. Helton, J.E. Berger, J.F. Czachura, K. Rasmussen, and M.J. Kallman Central nervous system characterization of the new Cholecystokinin B antagonist LY288513 Pharmacol. Biochem. Behav. 53 1996 493 502
24. A.I. Hersi, W. Rowe, P. Gaudreau, and R. Quirion Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats Neuroscience 69 1995 1067 1074
25. D.W. Hommer, M. Palkovits, J.N. Crawley, S.M. Paul, and L.R. Skirboll Cholecystokinin-induced excitation in the substantia nigra: evidence for peripheral and central components J. Neurosci. 6 1985 1387 1392
26. J.P. Huston, S. Schildein, P. Gerhardt, C. Privou, H. Fink, and R.U. Hasenöhrl Modulation of memory, reinforcement and anxiety parameters by intra-amygdala injection of cholecystokinin-fragments Boc-CCK-4 and CCK-8s Peptides 19 1998 27 37
27. S. Itoh, and H. Lal Influences of cholecystokinin and analogues on memory processes Drug Dev. Res. 21 1990 257 276
28. S. Itoh, A. Takashima, and G. Katsuura Preventive effect of cholecystokinin octapeptide on scopolamine-induced memory impairment in the rat Drug Dev. Res. 12 1988 63 70
29. G.L. Kovács, and D. de Wied Peptidergic modulation of learning and memory processes Pharmacol. Rev. 46 1994 269 291
30. J. Kulisevsky Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease Drugs Aging 16 2000 365 379
31. N. Ladurelle, G. Keller, A. Blommaert, B.P. Roques, and V. Dauge The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats Eur. J. Neurosci. 9 1997 1804 1814
32. I. Lena, B.P. Roques, and C. Durieux Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor subsites J. Neurochem. 68 1997 162 168
33. X.L. Li, S. Aou, T. Hori, and Y. Oomura Spatial memory deficit and emotional abnormality in OLETF rats Physiol. Behav. 75 2002 15 23
34. H.P. Lipp, and D.P. Wolfer Genetically modified mice and cognition Curr. Opin. Neurobiol. 8 1998 272 280
35. D.J. Lodge, J.L. Short, L.D. Mercer, P.M. Beart, and A.J. Lawrence CCK/dopamine interactions in Fawn-Hooded and Wistar-Kyoto rat brain Peptides 21 2000 379 386
36. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 193 1951 265 275
37. R.K. McNamara, and R.W. Skelton The neuropharmacological and neurochemical basis of place learning in the Morris water maze Brain Res. Rev. 18 1993 33 49
38. F.E. Miller, T.G. Heffner, C. Kotake, and L.S. Seiden Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion Brain Res. 229 1981 123 132
39. R. Morris Development of a water-maze procedure for studying spatial learning in the rat J. Neurosci. Methods 11 1984 47 60
40. S.S. Moy Impaired acquisition and operant responding after neonatal dopamine depletion in rats Pharmacol. Biochem. Behav. 52 1995 433 441
41. S. Nomoto, M. Miyake, M. Ohta, A. Funakoshi, and K. Miyasaka Impaired learning and memory in OLETF rats without cholecystokinin (CCK)-A receptor Physiol. Behav. 66 1999 869 872
42. B.A. Pappas, S.J. Murtha, G.A. Park, K.T. Condon, R.M. Szirtes, and S.I. Laventure Neonatal brain dopamine depletion and the cortical and behavioral consequences of enriched postweaning environment Pharmacol. Biochem. Behav. 42 1992 741 748
43. D.E. Pearson, L.A. Raskin, B.A. Shaywitz, G.M. Anderson, and D.J. Cohen Radial arm maze performance in rats following neonatal dopamine depletion Dev. Psychobiol. 17 1984 505 517
44. G.E. Ploeger, B.M. Spruijt, and A.R. Cools Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol Behav. Neurosci. 108 1994 927 934
45. L.A. Raskin, B.A. Shaywitz, G.M. Anderson, D.J. Cohen, M.H. Teicher, and J. Linakis Differential effects of selective dopamine, norepinephrine or catecholamine depletion on activity and learning in the developing rat Pharmacol. Biochem. Behav. 19 1983 743 749
46. K. Rasmussen, M.E. Stockton, J.F. Czachura, and J.J. Howbert Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity Eur. J. Pharmacol. 209 1991 135 138
47. T. Reum, U. Schäfer, C.A. Marsden, H. Fink, and R. Morgenstern Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry Neuropeptides 31 1997 82 88
48. A. Rex, M. Spychala, and H. Fink Treatment with reduced nicotinamide adenide dinucleotide (NADH) improves water maze performance in old Wistar rats Behav. Brain Res. 2004 [in press]
49. R.J. Rodgers, and N.J. Johnson Cholecystokinin and anxiety: promises and pitfalls Crit. Rev. Neurobiol. 9 1995 345 369
50. B.A. Shaywitz, J.W. Gordon, J.H. Klopper, and D.A. Zelterman The effect of 6-hydroxydopamine on habituation of activity in the developing rat pup Pharmacol. Biochem. Behav. 6 1977 391 396
51. R.D. Smith, B.R. Cooper, and G.R. Breese Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine J. Pharmacol. Exp. Ther. 185 1973 609 619
52. D.R. Smith, C.D. Striplin, A.M. Geller, R.B. Mailman, J. Drago, and C.P. Lawler Behavioural assessment of mice lacking D1A dopamine receptors Neuroscience 86 1988 135 146
53. S. Stancheva, M. Papazova, L. Alova, and M. Lazarova-Bakarova Impairment of learning and memory in shuttle box-trained rats neonatally injected with 6-hydroxydopamine. Effects of nootropic drugs Acta Physiol. Pharmacol. Bulg. 19 1993 77 82
54. K. Taghzouti, I. Léna, F. Dellu, B.P. Roques, V. Daudé, and H. Simon Cognitive enhancing effects in young and old rats of pBC264, a selective CCKB receptor agonist Psychopharmacology 143 1999 141 149
55. A. Takashima, and S. Itoh Memory impairment induced by CCK-8 antagonists in passive avoidance response of rat Drug Dev. Res. 18 1989 95 100
56. M. Takasuna, and T. Iwasaki Active and passive avoidance learning in rats neonatally treated with intraventricular 6-hydroxydopamine Behav. Brain Res. 74 1996 119 126
57. M.H. Teicher, S.L. Andersen, A. Campbell, H.A. Gelbard, and R.J. Baldessarini Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats Neurosci. Lett. 247 1998 99 102
58. F.J. Van der Staay Age-related changes in learning and memory in rats, assessed in the Morris water escape task The study of behavioral dysfunctions: an evaluation of selected animal models 2000 BCN Groningen 15 80
59. M. Voits, R.U. Hasenöhrl, J.P. Huston, and H. Fink Repeated treatment with cholecystokinin octapeptide improves maze performance in aged Fischer 344 rats Peptides 22 2001 1325 1330
60. M.M. Winnicka, and K. Wisniewski Bilateral 6-OHDA lesions to the hippocampus attenuate the facilitatory effect of CCK-8 us and caerulein on memory in rats Pharmacol. Res. 41 2000 347 353
61. Y. Yamaguchi, S. Kawashima, and H. Kobayashi Peptides in processes of learning and memory Neuro Endocrinol. Lett. 18 1998 103 110